Today, the SVP & GC of Catalent (NYSE: CTLT), Steven Fasman, bought shares of CTLT for $46.41K.
In addition to Steven Fasman, 9 other CTLT executives reported Buy trades in the last month. This is Fasman’s first transaction since reporting a Buy transaction on SIGA back in December 2009
See today’s analyst top recommended stocks >>
Based on Catalent’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $685 million and quarterly net profit of $82.7 million. In comparison, last year the company earned revenue of $617 million and had a net profit of $61.8 million. CTLT’s market cap is $5.8B and the company has a P/E ratio of 87.04. Currently, Catalent has an average volume of 1.24M.
Starting in February 2018, CTLT received 7 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services.
